Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

25 Apr 2013 07:00

RNS Number : 1743D
Biome Technologies PLC
25 April 2013
 



25 April 2013

 

Biome Technologies plc

("Biome", "the Company" or "the Group")

 

Trading Update

 

In advance of its Annual General Meeting today, Biome Technologies plc is pleased to announce its trading update for the three months ended 31 March 2013.

 

Trading Update

Total Group revenues achieved for the first three months of the year were £0.4m (Q1 2012: £4.6m including contributions from Biotec). We anticipate performance this year to be second half weighted and consequently expect sales growth to increase in both divisions as the year progresses.

 

The Group's cash position at 31st March 2013 was £5.8m (31st December 2012: £6.3m).

 

We continue to make progress with the strategy, as set out at our full year results, to commercialise and develop wholly owned intellectual property. and our performance remains in line with the Board's expectations.

 

Bioplastics Division

Q1 2013 revenues were £0.2m (Q1 2012: £4.3m including contributions from Biotec). This division is focused on developing high margin, application led products with enhanced level of functionality. Two key projects currently being undertaken include single use foodservice products and single use coffee capsules. These projects are progressing well and their contribution to revenues will become clearer during the second half of the year when they are expected to pass into a predominantly manufacturing phase.

 

In the first quarter, the division was awarded a grant by the Government-backed Technology Strategy Board (TSB) to investigate a bio-based alternative for the oil derived organic chemicals used in the manufacture of bioplastics. The £150,000 grant has been made to Biome Technologies as part of the TSB's 'Sustainable high value chemical manufacture through industrial biotechnology' competition, which funds projects that apply sustainable biobased feedstocks and biocatalytic processes for the production of chemicals. Biome has partnered with the University of Warwick's Centre for Biotechnology and Biorefining to work on the feasibility study that will be funded by this grant.

 

Stanelco RF Technologies Division

Q1 revenues were £0.2m (Q1 2012: £0.3m). This Division continues to see a wider variety of opportunities opening up as the business develops. As previously reported, a number of optical fibre furnace deliveries have been delayed due to some uncertainties in the Chinese fibre market although this market is expected to return to growth during the course of the year. Progress continues on the Durapipe project and the timing of delivery for ten pre-production units will be finalised over the next quarter, following time-based testing of the final pipe-work.

 

Stephen Baskerville, will be joining the Group to head up the Division as its Managing Director in August. Stephen joins the business following some twenty years in technical and commercial roles within the industry, most recently as Director of Heating Products at Inductotherm Heating and Welding Limited, a subsidiary of the global Inductotherm Group.

 

 

- Ends -

 

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

 

Daniel Stewart & Company plc

David Hart

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTNKQDKFBKDDQB
Date   Source Headline
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.